Saluda Medical Completes First U.S. CAP24 Paddle Lead Procedures
Saluda Medical has successfully completed the first U.S. surgical implantations of its FDA-cleared Evoke® CAP24™ paddle lead, representing an important advancement in closed-loop spinal cord stimulation (SCS) for chronic neurological disorders.
The initial surgery took place on 10 July at the University of Arkansas for Medical Sciences, followed by a second procedure on 14 July at the Advanced Surgery Center of Lancaster, Pennsylvania.
The CAP24™ paddle lead has been developed to support closed-loop neuromodulation by continuously monitoring the body's neural responses and automatically adjusting stimulation levels.
This approach is intended to provide more accurate and consistent therapy tailored to each patient's physiological needs.
With the introduction of CAP24™, Saluda Medical has expanded the use of its Evoke® Therapy to patients receiving paddle lead implants.
Paddle leads are widely used in spinal cord stimulation procedures by neurosurgeons and orthopaedic spine specialists and represent a significant share of the U.S. SCS market.
The company believes this achievement will strengthen the availability of objective, physiology-guided neuromodulation for a broader patient population while supporting further growth in the surgical segment.
The Evoke® System is backed by clinical studies that have shown sustained treatment benefits for up to 36 months, demonstrating the long-term effectiveness of its closed-loop spinal cord stimulation technology.
